Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: Relationship with infections, autoimmunity and disease progression

Leukemia and Lymphoma

Volumn 55, Issue 8, 2014, Pages 1768-1773

  Barcellini, Wilma ^a   Imperiali, Francesca G ^a   Zaninoni, Anna ^a   Reda, Gianluigi ^a   Consonni, Dario ^a   Fattizzo, Bruno ^a   Lonati, Silvia ^a,b   Nobili, Lucia ^a,b   Zanella, Alberto ^a   Cortelezzi, Agostino ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

autoimmunity; B chronic lymphocytic leukemia (B CLL); disease progression; infections; Toll like receptors (TLRs)

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; OFATUMUMAB; STEROID; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC RISK; HUMAN; HUMAN CELL; INFECTION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY; CANCER STAGING; COMPLICATION; DISEASE COURSE; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AUTOIMMUNITY; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84904863615     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.856426     Document Type: Article

References (38)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000; 4: 5-21.
3. Zaninoni A, Imperiali F G, Pasquini C, et al. Cytokine modulation of nuclear factor-kappa B activity in B-chronic lymphocytic leukemia. Exp Hematol 2003; 31: 185-190.
4. Scrivener S, Goddard R V, Kaminski E R, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44: 383-389.
5. Barcellini W, Montesano R, Clerici G, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol 2002; 71: 177-183.
6. Barcellini W, Capalbo S, Agostinelli RM, et al.; GIMEMA Chronic Lymphocytic Leukemia Group. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006; 91: 1689-1692.
7. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006; 33: 230-239.
8. Lad D P, Varma S, Varma N, et al. Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 2013; 54: 1012-1029.
9. Visco C, Novella E, Peotta E, et al. Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica 2010; 95: 1230-1232.
10. Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control 2012; 19: 18-25.
11. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15: 5-11.
12. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430: 257-263.
13. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
14. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36: 810-816.
15. Hua Z, Hou B. TLR signaling in B-cell development and activation. Cell Mol Immunol 2013; 10: 103-106.
16. Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 286-295.
17. Grandjenette C, Kennel A, Faure GC, et al. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007; 92: 1279-1281.
18. Muzio M, Scielzo C, Bertilaccio MT, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 507-516.
19. Mills KHG. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011; 11: 807-822.
20. Marta M, Andersson A, Isaksson M, et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008; 38: 565-575.
21. Hallek M, Cheson B D, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
22. Cramer P, Hallek M. Hematological cancer in 2011: new therapeutic targets and treatment strategies. Nat Rev Clin Oncol 2011; 8: 38-47.
23. Binet J L, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
24. Rose NR, Bona C. Defining criteria for autoimmune diseases. Immunol Today 1993; 14: 426-430.
25. Livak K J, S chmittgen T D. A nalysis of relative gene expression data using real-time quantitative PCR and the 2- ? ? CT method. Methods 2001; 25: 402-408.
26. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Blackwell Science; 2002.
27. Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press; 1993.
28. StataCorp. Stata statistical software: release 12. College Station, TX: StataCorp LP; 2011.
29. Rozkov a D, Novotn a L, Pytl i k R, et al. Toll-like receptors on B-CLL cells:expression and functional consequences of their stimulation. Int J Cancer 2010; 126: 1132-1143.
30. Arvaniti E, Ntoufa S, Papakonstantino Un, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia:distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011; 96: 1644-1652.
31. Jarnicki AG, Conroy H, Brereton C, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008; 180: 3797-3806.
32. den Haan JM, Kraal G, Bevan MJ. Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J Immunol 2007; 178: 5429-5433.
33. Nickerson K M, Christensen S R, Cullen J L, et al. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol 2013; 190: 1447-1456.
34. Lund F E. Cytokine-producing Blymphocytes-key regulators of immunity. Curr Opin Immunol 2008; 20: 332-338.
35. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005; 17: 230-236.
36. Visco C, Maura F, Tuana G, et al. Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. Clin Cancer Res 2012; 18: 1870-1878.
37. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012; 119: 4467-4475.
38. Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med 2012; 18: 1281-1291.